UMB Bank N.A.
Location
Missouri
Founded
1913-08-23
Website
Risk Signals
160 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., National Commercial Banks), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about UMB Bank N.A.
Live alerts from global media, monitored by Business Radar
2024-10-02 (thepharmaletter.com)
Judge dismisses $6.4 billion lawsuit against Bristol Myers Squibb
Bristol Myers Squibb won a legal victory as a New York judge dismissed a $6.4 billion lawsuit filed by UMB Bank on behalf of Celgene shareholders. The lawsuit alleged that Bristol Myers delayed drug approvals to avoid contingent value right (CVR) payments from its 2019 Celgene acquisition.
Read more
2024-10-01 (pm360online.com)
Bristol Myers beats $6.4 billion lawsuit over delayed cancer drug
(Reuters) - Bristol Myers Squibb won the dismissal on Monday of a $6.4 billion lawsuit claiming it cheated former Celgene shareholders by delaying federal approval for the cancer drug Breyanzi and two other drugs developed by Celgene.
Read more
2024-10-01 (investing.com)
Bristol Myers wins $6.4 billion lawsuit By Investing.com
Bristol Myers wins $6.4 billion lawsuit
Read more